Limits...
A case control study of sarcosine as an early prostate cancer detection biomarker.

Ankerst DP, Liss M, Zapata D, Hoefler J, Thompson IM, Leach RJ - BMC Urol (2015)

Bottom Line: HPLC-electrospray ionization mass spectrometry was used for serum sarcosine quantification.The AUC of sarcosine was not statistically different from random chance either for participants with any PSA value (52.2 %) or those with PSA values in the range of 2 to 10 ng/mL (54.3 %).Serum sarcosine should not be pursued further as a marker for the early detection of prostate cancer.

View Article: PubMed Central - PubMed

Affiliation: Department of Mathematics, Technische Universitaet Muenchen, Boltzmannstr 3, Garching, 85748, Germany. ankerst@uthscsa.edu.

ABSTRACT

Background: Sarcosine has been investigated as a prostate cancer biomarker with mixed results concerning its predictive power. We performed a case-control evaluation of the predictive value of serum sarcosine for early detection in a population-based cohort of men undergoing prostate-specific antigen (PSA) screening.

Methods: For analysis we used 251 cancer cases and 246 age-matched non-cancer cases from the San Antonio Biomarkers Of Risk (SABOR) screening study. For cancer cases, pre-diagnostic serum was utilized for sarcosine measurement. Controls were defined as men who had been followed at least for 5 years on study with no prostate cancer diagnosis; sarcosine was measured on the initial baseline serum. HPLC-electrospray ionization mass spectrometry was used for serum sarcosine quantification. The association of sarcosine with prostate cancer was assessed using area underneath the receiver-operating characteristic curve (AUC), and logistic regression adjusting for PSA, digital rectal exam, family history, age, race, and history of a prior negative biopsy. Among cancer cases, nominal logistic regression was used for the association of sarcosine with Gleason grade.

Results: Sarcosine levels were overlapping between the prostate cancer cases (median 15.8 uM, range 6.2 to 42.5 uM) and controls (median 16.2 uM, range 6.4 to 53.6 uM). The AUC of sarcosine was not statistically different from random chance either for participants with any PSA value (52.2 %) or those with PSA values in the range of 2 to 10 ng/mL (54.3 %). Sarcosine was not predictive of Gleason score and added no independent predictive power to standard prostate cancer risk factors for detection of prostate cancer (all p-values > 0.05).

Conclusions: Serum sarcosine should not be pursued further as a marker for the early detection of prostate cancer.

No MeSH data available.


Related in: MedlinePlus

Boxplots of sarcosine measurements among cancer cases (red) and controls (green) in the SABOR study for all cases and controls (left, 246 cases, 251 controls) and those with PSA in the 2 to 10 ng/mL range (right, 188 cases, 53 controls)
© Copyright Policy - OpenAccess
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC4591628&req=5

Fig1: Boxplots of sarcosine measurements among cancer cases (red) and controls (green) in the SABOR study for all cases and controls (left, 246 cases, 251 controls) and those with PSA in the 2 to 10 ng/mL range (right, 188 cases, 53 controls)

Mentions: Sarcosine levels were overlapping between the prostate cancer cases (median 15.8 uM, range 6.2 to 42.5 uM) and controls (median 16.2 uM, range 6.4 to 53.6 uM); see Fig. 1 and Table 1. The AUC of sarcosine was not statistically different from random chance either for participants with any PSA value (52.2 %) or those with PSA values in the range of 2 to 10 ng/mL (n = 53 controls, 188 cases, AUC 54.3 %). There was no independent predictive power of sarcosine for prediction of prostate cancer, controlling for PSA, DRE, and the other risk factors for prostate cancer (all p > 0.05, Table 2). Sarcosine similarly failed to be predictive of high- versus low-grade cancer (all p > 0.05).Fig. 1


A case control study of sarcosine as an early prostate cancer detection biomarker.

Ankerst DP, Liss M, Zapata D, Hoefler J, Thompson IM, Leach RJ - BMC Urol (2015)

Boxplots of sarcosine measurements among cancer cases (red) and controls (green) in the SABOR study for all cases and controls (left, 246 cases, 251 controls) and those with PSA in the 2 to 10 ng/mL range (right, 188 cases, 53 controls)
© Copyright Policy - OpenAccess
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC4591628&req=5

Fig1: Boxplots of sarcosine measurements among cancer cases (red) and controls (green) in the SABOR study for all cases and controls (left, 246 cases, 251 controls) and those with PSA in the 2 to 10 ng/mL range (right, 188 cases, 53 controls)
Mentions: Sarcosine levels were overlapping between the prostate cancer cases (median 15.8 uM, range 6.2 to 42.5 uM) and controls (median 16.2 uM, range 6.4 to 53.6 uM); see Fig. 1 and Table 1. The AUC of sarcosine was not statistically different from random chance either for participants with any PSA value (52.2 %) or those with PSA values in the range of 2 to 10 ng/mL (n = 53 controls, 188 cases, AUC 54.3 %). There was no independent predictive power of sarcosine for prediction of prostate cancer, controlling for PSA, DRE, and the other risk factors for prostate cancer (all p > 0.05, Table 2). Sarcosine similarly failed to be predictive of high- versus low-grade cancer (all p > 0.05).Fig. 1

Bottom Line: HPLC-electrospray ionization mass spectrometry was used for serum sarcosine quantification.The AUC of sarcosine was not statistically different from random chance either for participants with any PSA value (52.2 %) or those with PSA values in the range of 2 to 10 ng/mL (54.3 %).Serum sarcosine should not be pursued further as a marker for the early detection of prostate cancer.

View Article: PubMed Central - PubMed

Affiliation: Department of Mathematics, Technische Universitaet Muenchen, Boltzmannstr 3, Garching, 85748, Germany. ankerst@uthscsa.edu.

ABSTRACT

Background: Sarcosine has been investigated as a prostate cancer biomarker with mixed results concerning its predictive power. We performed a case-control evaluation of the predictive value of serum sarcosine for early detection in a population-based cohort of men undergoing prostate-specific antigen (PSA) screening.

Methods: For analysis we used 251 cancer cases and 246 age-matched non-cancer cases from the San Antonio Biomarkers Of Risk (SABOR) screening study. For cancer cases, pre-diagnostic serum was utilized for sarcosine measurement. Controls were defined as men who had been followed at least for 5 years on study with no prostate cancer diagnosis; sarcosine was measured on the initial baseline serum. HPLC-electrospray ionization mass spectrometry was used for serum sarcosine quantification. The association of sarcosine with prostate cancer was assessed using area underneath the receiver-operating characteristic curve (AUC), and logistic regression adjusting for PSA, digital rectal exam, family history, age, race, and history of a prior negative biopsy. Among cancer cases, nominal logistic regression was used for the association of sarcosine with Gleason grade.

Results: Sarcosine levels were overlapping between the prostate cancer cases (median 15.8 uM, range 6.2 to 42.5 uM) and controls (median 16.2 uM, range 6.4 to 53.6 uM). The AUC of sarcosine was not statistically different from random chance either for participants with any PSA value (52.2 %) or those with PSA values in the range of 2 to 10 ng/mL (54.3 %). Sarcosine was not predictive of Gleason score and added no independent predictive power to standard prostate cancer risk factors for detection of prostate cancer (all p-values > 0.05).

Conclusions: Serum sarcosine should not be pursued further as a marker for the early detection of prostate cancer.

No MeSH data available.


Related in: MedlinePlus